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GOOD ENOUGH TO USE FOR RESEARCH, BUT NOT 

GOOD ENOUGH TO BENEFIT FROM THE RESULTS 

OF THAT RESEARCH: ARE THE CLINICAL HIV 

VACCINE TRIALS IN AFRICA UNJUST? 

Ruqaiijah Yearby* 
INTRODUCTION 
The epidemic of the Human Immunodeficiency Virus (HIV) infec­
tion in Sub-Saharan Africa,l the region most affected by the HIV pan­
demic and where HIV is the leading cause of death, is reaching 
insurmountable proportions. In fact, out of the 36.1 million HIV in­
fections worldwide, 25.3 million, seventy percent, are in Sub-Saharan 
Africa. 2 Additionally, of the more than 15.000 people who are in­
fected with HIV every day, ninety-five percent of the cases are in 
populations that live in developing countries such as those located in 
Sub-Saharan Africa.3 Due to the significant number of Africans in· 
fected with HIV, many researchers and ethicists have focused their 
attention on granting Africa fair opportunity to have access to clinical 
HIV vaccine trials. But fair opportunity to participate in clinical HIV 
vaccine trials does not guarantee that Africans will benefit from the 
research because of the very nature of clinical trials. 
Assistant Professor of Law, Loyola University Chicago School of Law. I am grateful to 
John Blum, Roderick Nelson, Lawrence Singer, Neil Williams, and Ayanna Yearby for gener­
ously sharing their insights and comments on this work and for suggesting opportunities for 
future work. I would also lik" to thank my research assistants, Simone Ortuanya and Timothy 
Rozoff, for their invaluable contributions and Elissa Koch for numerous thoughtful discussions. 
\-tany thanks to the symposium participants, particularly Michele Goodwin and the editors at the 
DePaul Law Review , for putting together an excellent symposium that featured numerous valua­
hIe contributions . 
1. Sub-Saharan Africa includes all of the countries of Africa except eight. The countries not 
included in Sub-Saharan Africa are the Wes tern Sahara, Morocco. Algeria, Tunisia, Libya, 
Egypt , Sudan, and J::ritr~a. See The Or. for HIV Info., Univ. of Cal. , San Francisco Sch. of Med., 
Sub -Saharan Africa Map (2003), at http://hivinsite.ucsf.edu (last visited Feb. 4, 2004). 
2. See A Difference of15 Years, WASH. POS1, July 4, 2000, at http://www.washingtonpost.comJ 
wp-srv/world/daily/julyOO/aidsgraphic.htm (las t visited Feb. 4, 2004). 
3. See Jose Esparza, An HIV Vaccine: How and When? , 79 BULL. WORLD HEALTH ORO. 1133 
(2001); BARNEY S. GRAHAM, NATIONAL INSTITUTES OF HEALTH VACCINE R ESEARCH CENTER 
REPORT, CLINICAL TRIALS OF HIV VACCINES 2 (2001). 
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A clinical trial consists of a research study that uses human subjects 
to evaluate the efficacy of new drugs and treatments.4 The purpose of 
clinical trials is to develop new treatments to prevent or treat dis­
eases.S Although trials offer the prospect of benefits for the individu­
als participating in the trials, in reality, many subjects do not receive a 
net benefit because the new drugs and treatments have unknown side 
effects and dangers.6 Rather, the benefit is to society.7 In an attempt 
to protect the lives of individuals participating in these trials, the 
United States and other nations developed ethical principles applica­
ble to clinical trials. The three fundamental ethical principles are:8 
Respect of Persons,9 Beneficence,lO and Justice. These ethical princi­
ples prevent the manipulation and exploitation of research subjects 
for the benefit of society as a whole. Furthermore, these principles 
provide the framework for researchers in the United States and 
abroad regarding what is humane and what the acceptable risk is for 
research subjects to bear.ll In the United States, these principles have 
been codified and are therefore compulsory.12 Abroad, these princi­
ples are widely accepted and appear in documents of international 
ethical principles.13 Of these ethical principles, this Article will focus 
on the Justice principle and its application to clinical trials. 
4. TOM BEAUCHAMP & JAMES CHILDRESS, PRINCIPLES OF BIOMEDICAL ETHICS 441 (4th ed. 
1994). 
5. ld. 
6. ld. 
7. Id . 
8. These three principle; are found in th e Belmont Report: Ethical Principles and Guidelines 
for the Protection of Human Subjects of Riomedical and Behavioral Research. See The Belmont 
Report, 44 Fed. Reg. 23,192, 23,194 (Apr. 18, 1979). This document was drafted by the National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research in 
1976 and published in the Federal Registe r. ld. 
9. The doct rine of Respect of Persons includes two main e thical canons: autonomy and pro. 
tection. Researchers must treat human research subjects as autonomous agents and provide 
protections for those with diminished autonomy. ld . at 23,193. 
10. Benefict:l1ce requires researchers to "not only respect the autonomy of the research sub· 
jects but also make an effort to secure their well·being." ld. at 23,194. 
11. ld. 111is is important because most of the countries in which the United States is fund ing 
and conducting clinical trials do not have effective mechanisms available to review the ethical 
implications of the research. See UNA IDS Report: UNA IDS Sponsored Regional Workshops To 
Discuss Eth ical Issues in Preventive H1 V Vaccine Trial;~ U.N. Progamme on HIV and AIDS 
(UNAIDS), at 8, UNAIDS Doc. 00 036 (2002). 
12. 45 C.F.R. § 46.101 (2003). 
13. In fact the principle of Justice was found only in the Belmont Report until 2000, when the 
World Medical Associa tion added the principle to the Declaration of Helsinki , a renowned docu· 
ment of bioethics for clinical trials . The Belmont Report, 44 Fed. Reg. at 23,192; see also WORLD 
MED. ASS'N, THE DECLARATION OF HELSINKI (2002), available at http://www.wma.net/e/policy/ 
b3.htm (last visited Feb. 4, 2004) . 
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The expansive doctrine of Justice encompasses the principles of 
fairness, equity, and equality.14 This broad doctrine of Justice has a 
limited application to clinical trials in that it demands that the "soci­
ety" that benefits from the results of the study must include individu­
als similar to those who participate in the study.15 In this context, 
Justice addresses issues of a population's right to be treated equally, 
while Respect of Persons and Beneficence address the rights of an 
individual. Even though statements of Justice can be found in the eth­
ical guidelines of most countries and medical organizations,16 this Ar­
ticle will focus on the statement of Justice found in two of the most 
renowned statements of ethics: the United States's The Belmont Re­
port: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research (Belmont Report) and the World Medical Asso­
ciation's Declaration of HelsinkiY As this Article will show, however, 
some researchers have perverted the principle by consistently ignoring 
the requirements of Justice when conducting research in developing 
countries or regions such as Sub-Saharan Africa. 18 Individuals who 
participate in clinical trials in Africa bear the same burden that Amer­
ican research subjects bear but do not receive the same benefits. 
Thus, one must ask why Africans are good enough to use for medical 
research but not good enough to be included in the "society" that ben­
efits from that research. 
Illustrative examples of this problem are the clinical trials con­
ducted by some American researchers to prevent the spread of HIV in 
Sub-Saharan Africa. In the late 1990s, researchers from the United 
States traveled to Sub-Saharan Africa and conducted drug trials.19 
Many of these trials involved testing the effectiveness of new treat­
ments and developing a shorter length of treatment for drugs already 
in use to prevent mother-to-child HIV transmission.20 Unfortunately, 
because of the astronomical cost of these new treatments and drugs, 
14. The Belmont Report, 44 Fed. Reg. at 23,196; see also WORLD M ED. ASS'N, supra note 13. 
15. The Belmont Report , 44 Fed. Reg. at 23,196; see also WORLD MED. ASS'N, supra note 13. 
16. Recently, many countries, such as the United Kingdom, Canada, Nepal , Uganda, and Bra­
zil, have revised their ethical guidelines to address access to post-trial benefits. See Alice Page, 
Prior Agreements in International Clinical Trials: Ensuring Ihe Benefits of Research to Developing 
Co untries, 3 YAI L J. H EA LTH POL'y, L. & E T H[CS 35, 50 (2002). Nevertheless. many of the 
guidelines are not compulsory and have no enforcement mechanism. Id. 
17. The Belmont Report, 44 Fed. Reg. at 23,194; see also WORLD ME l). ASS'N, supra note 13. 
18. For example, researchers conducting AZT drug trial·. in Africa to prevent mother-lo-child 
transmission offered some subjects placebos even though the same trials conducted in the 
United Stales provided each subject with drugs. Id. For more discussion , see infra subpart 
II(B) . 
19. David Studdert & Troyen Brennan. Clinical Trials in Developing Countries: Scientific and 
Ethical Issues, 169 M El) . J. AUSTL. 545 (1998). 
20. Id. 
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few Sub-Saharan African countries and citizens would have had access 
to these treatments and drugS. 21 Therefore, relatively few Africans 
afflicted with HIV directly benefited from the results of this re­
search.22 Many researchers and ethicists questioned why Africans 
should bear the burden of participating in the research when they did 
not benefit from the results of the studies.23 In response to these 
questions, researchers asserted that exorbitant costs meant that "soci­
ety" should only include those who could afford treatment once it was 
patented and packaged by corporations.24 Moreover, some research­
ers argued that Justice applies to an individual's right to participate in 
clinical trials.2s But who does the Justice principle protecting-indi­
viduals or populations? 
In the case of the HIV drug trials, leading ethicists asserted that 
neither individual Africans nor the African population benefited from 
these trials. As a result of these problems and negative publicity, 
many of these studies were terminated before completion or the struc­
ture of the trials was changed because of the violations of individual 
and population rights. Nevertheless, neither research~rs nor ethicists 
reached any consensus regarding the requirements of the Justice prin­
ciple in clinical trials conducted in Africa and other developing coun­
tries.26 Questions of who is included in the "society" that henefits 
from a particular study and whether the Justice principle may be lim­
ited by concerns related to cost are paramount issues that persist and 
need answering as researchers commence HIV vaccine trials in Africa . 
The first HIV vaccine trial was conducted in Africa in 1987 by a 
French doctor who immunized himself and a small group of Zairians 
21. Ronald Bayer. The Debate over Maternal·Fetal HIV Transmission Prevention Trials in / IF 
rica, Asia, and the Caribbean: Racist Exploitation or Exploitation of Racism?, 88 AV!. J. Pen. 
HEALTH 567, 570 (1998). 
22. [d. 
23. Georgt: Annas & Michael Grodin , Human Rights and Waternal-I:etal HIV Transmission 
Prevention Trials in Africa, 88 AM. J. PUB. HEALTH 560, 560-61 (1998); R.A. Crouch & J.D. 
Arras, A7T Trials and Tribulations, 28 H ASTINGS CENTI.R REP. 26, 29 (1998); L.H. G lantz, Re­
search in Developing Countries: Taking Benefit Seriously, 28 H ASTINGS CENTER R EP. 38, 40-42 
(1998); Marcia Angell, The Ethics of Clin ical Research in the Third World. 337 NEW ENG. J . 
MED. 847, 847-48 (1997). 
24. See Pett:r Lurie & Sidney Wolfe, Unethical Trials of Interventions To Red/lce Perinatal 
Transmission of Human Immunodeficiency Virus in Developing Countries, 337 ~, \V r "" ,. 1. 
MED. 853, 854-55 (1997). 
25. Harold Varmus & David Satcher, Ethical Complexities of Condu('ring i<esearch in Devel­
oping Countries, 337 NEW ENG. 1. MED. 1003,1004 (1997). 
26. Studdert & Brennan, supra note 19, at 545. 
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with an investigational HIV vaccine.27 According to a New York 
Times article published at the time, the reason the study was con­
ducted in Zaire was because "it was easier to get official permission 
[in Zaire] than in France,"?8 not because the population would benefit 
from the trials.29 Since that trial, only four other HIV vaccine trials 
have been conducted in Africa, three of which began in 2003.30 The 
trials currently being conducted in Africa, unlike the drug trials in the 
late 1990s and the first HIV vaccine trial, are not inherently discrimi­
natory in their practice. However, it is questionable whether Africans 
will benefit from these trials because, in part, researchers have not 
guaranteed Africans access to the HIV vaccine if it proves effective. 
In the past, the Belmont Report and the Declaration of Helsinki 
would provide the framework to address this problem; however, now 
some of the HIV vaccine trials are funded by private industry and are 
exempt from these requirements. 31 For instance, the International 
AIDS Vaccine Initiative (IAVI), an international scientific organiza­
tion, funds the HIV vaccine trial conducted in Uganda.32 Neither the 
Belmont Report, which only applies to research funded by the U.S. 
government,33 nor the Declaration of Helsinki, which applies to all in­
ternational trials but is only advisory,34 applies to that trial. Some 
scholars have suggested requiring researchers and funders to enter 
into prior agreements with individual countries to negotiate the pro­
posed benefits before the research begins; however, these agreements 
27. The Zairians tested were HIV-negative before receiving the vaccine. Nicholas A. Chris­
takis, The Elhical Design of an AIDS Vaccine Trial in Africa, 18 HASTINGS CENTER REP. 31 , 31 
(1988). 
28. Z aire, Ending Secrecy, Auacks AIDS Openly, N.Y. TIMES, Feb. 18, 1987, at AI, cited in 
Christakis, supra note 27, at 3l. 
29. In an article published in the Nature journal, Dr. Daniel Zagury claims that he not only 
had the full support of the Zairian government but also worked with a group of Zairian scientists 
on th(; project. {d. Dr. Zagury used this to justify the vaccine trial; however, human research 
guidelines of the World Health Organization and the Council for Int<.! rnationa l Organizations o f 
Medical Scie nces required tha t the ett,ical standards, which are applied to research studies con­
ducted in the researche r's own country, must also be applied to research studies conducted in 
developing countries. Christakis, supra note 27, at 3l. 
30. See Roy Mugerwa et aI. , First Trial of the HIV-J Vaccine in AJi'iea: Ugandan Experience, 
324 BRITISH MED. J . 226, 228 (2003); NAT'L INST. OF H EALTH, SAFETY OF AN HIV VACCINE 
(AVX101) IN HIV UNINFECTED VOLUNTEERS IN THE UNITED STATES AND SOUTH AFRICA 
(2003) , available at http://www.c1inicaltrials .gov (last visited Feb. 4, 2004); NAT'L INST. OF 
HEALTH, SAFETY Of AND IMMUNE SYSTEM R ESPONSE TO AN HIV VACCINE (EP HIV-1090) IN 
HIV UN INFECTED A DULTS (2003), available at http://www.clinicaltrials.gov (last visited Feb. 4, 
2004). 
31. Richard Rettig, The Industrialization of Clinical Research, H hALTH Aff., Apr.-May 2000, 
at 129, 131. 
32. Mugerwa et aI., supra note 30, at 228. 
33. 4S c.F.R. § 46.101 (2003) . 
34 . WORLD MED. ASS'N, supra note 13. 
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are not compulsory and provide no additional mechanism of enforce­
ment beyond the advisory requirement of the Declaration of Hel­
sinki.35 The best way to ensure that the African populations that bear 
the burden receive a benefit is to draft and implement a compulsory 
international document of ethical protections enforced by an interna­
tional organization. 
This Article explores the ethical principle of Justice and its applica­
tion to clinical trials in developing countries through the lens of the 
current HIV vaccine trials in Sub-Saharan Africa. Part II examines 
the history of the Justice principle as it pertains to clinical trials and 
answers the question of who should be included in the "society" that 
benefits from the results of the research. The benefits of the Justice 
principle, fair access to the results of clinical trials, are compared to 
the benefits of fair opportunity to clinical trials in Part III, which re­
views the problems with past clinical HIV drug trials conducted in 
Sub-Saharan Africa. Part IV briefly surveys the current HIV vaccine 
trials underway in Africa, discusses some of the failures of researchers 
to apply the principle of Justice, and suggests a possible mechanism to 
ensure that fu ture clinical trials conducted in Africa provide a benefit 
to a "society" that includes Africans. 
II. T HE HISTORY OF THE JUSTICE PRINCIPLE AND ITs 
ApPLICATION TO CLINICAL TRIALS 
The Justice principle encompasses fairness and equity.36 Norman 
Daniels, a Professor of Ethics at the Harvard School of Public Health, 
states that Justice requires everyone be given a fair opportunity to 
resources including health careY Aristotle defined Justice in terms of 
equality: equals must be treated equally and unequals must be treated 
unequaUy.38 The French philosopher, Rosseau, said that because all 
men are born equal one must "treat all men [and women] with com­
plete equality and justice will prevail."39 But how is Justice achieved? 
The principle of Justice is an active process used to remedy or prevent 
what would arouse a sense of injustice.40 These same general princi­
ples of Justice are applied to protections of human subjects participat­
ing in clinical trials. There are two main documents that govern 
35. Page, supra note 16, at 38-43 . 
36. The Belmont R eport , 44 Fed. Reg. 23,192. 23,194 (Apr. 18. 1979). 
37. NORMAN D ANIELS, JUST H EALTH CARE 34-58 (1985). 
38. B EAUCHA MP & CHILDRESS. supra note 4, at 328. 
39. JEAN-JACQUES ROUSSEAU, THE SOCIAL CONTRACT 4 (Maurice r:ranston trans. , Penguin 
Books 1968) (1762). 
40. EDWARD CAHN, THE SENSE OF JUSTICE 14-15 (1949). 
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international clinical trials and espouse the requirements of Justice: 
the Belmont Report and the Declaration of Helsinki. 41 According to 
these documents, Justice requires that populations used for research 
be treated equally and fairly.42 As a review of these documents 
shows, the application of this principle to clinical trials has a long, sor­
did history-internationally and in the United States. 
The first discussion concerning the allocation of burdens and bene­
fits of clinical trials appeared in the United States's Belmont Report.43 
In the early 1970s, the U.S. Senate Committee on Labor and Human 
Resources held hearings on some of America's most egregious clinical 
trials, such as the Tuskegee Syphilis Study conducted from 1932 
through 1972, in which poor African-American men were denied ac­
cess to standard treatment.44 As a result of the hearings, Congress 
enacted the National Research Act of 1974, which required the U.S. 
Department of Health, Education, and Welfare (HEW)45 to develop 
and publish policies for the protection of human subjects in the Code 
of Federal Regulations.46 In addition, Congress created the National 
Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (Commission)47 and imposed a moratorium on 
41. The precursor to international ethical protections or human subjects participating in 
clinical tria ls was the Nuremberg Codl! (Code) in 1947. which was developed in response to the 
Trials of War Criminals before the Nuremberg Military Tribunals. See NUREMBERG CODE 
(1947) , available at http://ohsr.od.nih.gov/nuremberg.php3 (last visited Feb. 4, 2004). The Code 
does not explicitly discuss the equal distrihution of burdens and benefits from the results of 
clin ical trials; however, the Code notes that experiments should yield fruitful results for the good 
of society. Although this statement does not directly address who is included in society, it served 
as the building block of the Justice principle defined in the Belmont Report. See The Belmont 
Report, 44 Fed. Reg. at 23,1 92. 
42. TIle Belmont Report, 44 Fed. Reg. at 23 ,192. 
43. [d. 
44. See gen.erally JAMES H. JONES, BAD BLOOD: TJ-IL TUSKEGEE SYPHILIS E XPERIMENT 
(1981). 
45 . The U.S. Department of Health, Education, and Welfare was renamed the U.S. Depart­
ment of Health and Human Services in 1980. See Department of Education Organization Act, 
Pub. L. No. 96-88, § 509(e), 93 Stat. 6Y5 (1979) (codified at 20 U.S.c. § 3508 (2000». 
46. See National Research Act of 1974, 42 U.S.c. § 2891 (2000). 
47. The Commission wa:; composed of eleven members appointed by the Secretary of HEW. 
The National Research Act advised the Secretary of HEW to choose the members of the Com­
mission from distinguished individuals from the fields of medicine, law, ethics, theology, philoso­
phy, humanities, health administration, government, public affairs, and the biological, physical, 
behavioral, and social sciences. ld. Five of the members of the Commission had to be individu­
als engaged in biomedical or behavioral research involving human subjects. ld. Members of the 
Commission included Dorothy 1. Height, President of the National Council of Negro Women, 
Inc .. Dr. Albert R. Jonsen, Professor Emeritus of Medical History and Ethics at the U niversity 
of Washington, and Patricia King, the Carmack Waterhouse Professor of Law, Medicine, E thics, 
and Public Policy at Georgetown University Law Center. See The Belmont Report, 44 Fed . Reg. 
at 23,192. 
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research conducted or supported by HEW until adequate protections 
for research subjects were developed.48 
The duties of the Commission were to identify the basic ethical 
principles that should govern medical and behavioral research involv­
ing human subjects, advise the Secretary of HEW on what changes to 
make to HEW policies governing clinical trials, and draft final guide­
lines that would ensure that researchers conducted clinical trials in 
accordance with these ethical principles.49 To achieve this end, the 
Commission reviewed the existing HEW framework, recommended 
changes to the Secretary of HEW, and revised HEW's policy pertain­
ing to clinical trials in the Belmont Report.5o The Belmont Report 
was an outgrowth of the Commission's deliberations regarding ethical 
protections at monthly meetings and a 1976 conference at the Smith­
sonian Institute's Belmont Conference Center.51 In 1979, the Bel­
mont Report was published in the Federal Register as the official 
policy statement of basic ethical principles and guidelines of HEW re­
garding research with human subjects.52 In the Belmont Report , the 
Commission selected Justice as one of the three fundamental ethical 
principles53 and defined Justice by first asking the question: "Who 
ought to receive the benefits of research and bear its burdens?"54 To 
answer this question and establish the contours of Justice, the Com­
mission defined what is just and what is unjust. 
According to the Commission, an injustice occurs during clinical tri­
als when a benefit is denied to a person without gooJ reason or a 
burden is unduly imposed on a person, "whereas Justice requires that 
equals be treated equally. "55 In the context of clinical trials, the Bel­
mont Report states: 
Whenever research supported by public funds leads to the develop­
ment of therapeutic devices and procedures, justice demands both 
that these not provide advantages only to those who can afford 
48. 42 u.s.c. § 289l. 
49. ld. 
50. The Commission issued several reports that addressed the need for ethical protections and 
a summary of their monthly meetings; however, the Be lmont Report was their final statement of 
ethical principles that govern medical and behavioral research. See NAT'L iNST. OF H EALTH, 
GUIDELINES FOR THE CONDUCT OF RESEARGi INVOLVING HUMA1< SUBJECTS AT THE NATIONAL 
hSTfTLTES OF HEALTH (1995), available at http://ohsr.od.nih.gov/guidelines.php3 (last visited 
Feb. 4, 2004). After drafting the Belmont Report , the Commission was dissolved in 1978. Id. 
5l. ld. 
52. In J979, HEW began revising its policies regarding clinical trials. The revisions became 
fi nal in 1981. See The Belmont Report , 44 Fed. Reg. a t 23,192. 
53. The two other principles wen; Respect for Persons and Beneficence. For a definition of 
each of these ethical principles, see supra notes 9 and 10. 
54. ld. at 23,194 . 
55. ld. 
2004] GOOD ENOUGH TO USE FOR RESEARCH 1135 
them and that such research should not unduly involve persons from 
groups unlikely to be among the beneficiaries of subsequent applica­
tions of the research.56 
Thus, Justice prevents one population or group from being used for 
research without a benefit, while other populations or groups not used 
for research receive a benefit. The Commission's statement of Justice 
evolved from its view of the historical use of many vulnerable and 
disadvantaged populations for research that lead to the exploitation of 
these populations for the good of society.57 Furthermore, the Com­
mission specifically mentioned the need to apply the Justice principle 
to clinical trials to prevent other atrocities, such as those committed in 
the Tuskegee Syphilis Study and in the Nazi concentration camps.58 
Thereafter, the Commission applied this definition to evaluate who 
should bear the burden and receive the benefits of clinical research. 
To protect human subjects in clinical trials, the Commission deter­
mined that when research subjects are selected, "the principle of jus­
tice gives rise to moral requirements that there be fair procedures and 
outcomes in the selection of research subjects. "59 Justice requires 
that the selection of human subjects for clinical trials be scrutinized to 
ensure that the population is not selected merely because research 
subjects are easily available, in a compromised position, or readily 
manipulated.60 Moreover, in government-funded clinical trials to de­
velop drugs and vaccines in the United States and abroad , Justice dic­
tates that subjects from vulnerable populations receive a benefit from 
the resul ts of the trials.61 
The Belmont Report 's iteration of the Justice principle was codified 
in 1986 in the Code of Federal Regulations.62 Initially the principle 
was only applicable to research conducted and funded by HEW, but 
in June 1991, the Belmont Report was changed to govern all federally 
funded research.o3 Today, before U.S. scientists conduct government­
funded clinical trials in the United States and abroad, the researcher 
must comply with the above-mentioned requirements of the Justice 
principle.64 The problem with the Belmont Report is that it only ap­
56_ l d. (emphasis added). 
57. The Commission noted the relevance of Justice because of the egregious ethical viola tions 
commi tted in the Tuskegee Syphilis Study and in the Nazi concentra tion camps. ld_ 
58. NAT'L INST. OF HEALTH, supra note 50. 
59. The Belmont Report, 44 Fed. Reg. at 23,192. 

60 _ ld, at 23,1 94_ 

61. ld . at 23,197_ 

62_ NAT'L INST, OF H EALTH, supra nute 50. 

63_ 56 Fed_ R eg, 28,003, 28,003 (June 18, 1991) , 

64 , Before U .S, researche rs begin clinical trials, they mus t submit a written assurance to the 

appro priate Institutional Review Boa rd (IRB)- 45 C,ER. § 46.101(a )(2) (2002)_ A complete 
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plies to trials conducted or funded by the United States.65 Trials 
funded by private industry do not have to comply with the Belmont 
Report's protections. These trials would be governed by international 
law, such as the Declaration of Helsinki, which includes some of the 
same ethical principles featured in the Belmont Report. 
The Declaration of Helsinki, drafted and adopted in 1964 by the 
World Medical Association, is a statement of ethical standards that 
was designed as a guide to physicians and others participating in medi­
cal research involving human subjects, in addition to the responsibili­
ties imposed by their own countries.66 In 2000, thirty-six years after 
the adoption of the document,67 the World Medical Association 
amended the Declaration of Helsinki to include the Justice principle.68 
The impetus of this revision was a proposal submitted by the Ameri­
can Medical Association (AMA) in 1997, which significantly revised 
the Declaration of Helsinki.69 The AMA's revisions were issued as a 
World Medical Association document and discussed at the World 
Medical Council's 153rd Session in Santiago, Chile in April 1999.70 
The revisions submitted produced considerable debate and contro­
versy because they addressed the use of placebos in research and the 
standard of care ethically required for subjects participating in clinical 
trials in developing countries.7! After debating the revisions at con­
ferences, symposiums, and workshops, the World Medical Association 
adopted the revisions on October 7, 2000, making it the first interna­
written assurance includes a statement of the ethical principles protecting the rights and welfare 
of human research subjects based on the ethical principles of the Belmont Report. 45 CF.R. 
§ 46.103(b)(I) (2002). An IRB, a board found in all kderal agencies and universities that con­
duct biomedical research, reviews all written assurances in application for clinical trials. See 10 
CF.R. § 745.101 (1991); 28 c.F.R. § 46.101 (1991); 45 C.F.R. § 46.109 (2002). The IRR reviews 
the proposal to ensure that the proposed trials are ethical and has the authority to "approve, 
require modifications in (to secure approval), or disapprove" any application. 45 C.F.R. 
§ 46.109(a) . 
65. 45 C.F.R. § 46.10l. 
66. Research governed by the Declaration of Helsinki includes research involving identifiable 
human material or data . See WORLD MED. ASS'N, supra note 13. 
67. The 2000 revision of the Declaration of Helsinki was the fifth revision to the document. 
Id. The document was revised in 1975, 1983, 1989, 1996, 2000, and 2002. Id. 
68. The latest version of the Declaration of Helsinki was published in 2002; howeveI. the prin­
ciple of Justice fir st appeared in the Declaration of Helsinki in 2000. The World Medical As:;oci ­
ation amended the Declaration of Helsinki at the 52nd World Medical Association General 
Assembly Meeting in Edinburgh, Scotland in October 2000. The World Medical Association in 
Washington added a note of clarification in 2002, but this revision Jid ;lOt affect the statement of 
the Justice principle. Id. 
69. Delon Human & Sev S. Fluss , Th e World Medical Association's Declaration of Helsinki: 
Historical and COl1lemporary Perspective 1, 13-15 (2001) , at http://www.wma .net/e/ethicsunit/hei­
sinki.htm (last visited Nov. 17, 2003). 
70. Id . at 13. 
71. Id. at 15. 
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tional ethical document to recognize the Belmont Report's Justice 
requirement.72 
Comparable to the Belmont Report, the Declaration of Helsinki ad­
vises medical researchers that clinical trials are only just if the popula­
tion used for research benefits. The Declaration of Helsinki states: 
"[M]edical research is only justified if there is a reasonable likelihood 
that the populations in which the research is carried out stand to bene­
fit from the results of the research. "73 Hence, the Justice principle 
should be used by researchers in evaluating who should participate in 
clinical trials by first identifying those populations that will benefit 
from the results of the trials.74 If the population will not benefit from 
the results of the research, then the researcher must choose subjects 
from another population.75 The incorporation of the Justice principle 
into one of the premier international documents regarding human 
rights and clinical trials demonstrates clearly the importance of the 
principle in protecting research subjects across the world . Unfortu­
nately, the Declaration of Helsinki is not compulsory. 
Nevertheless, Professors Francis Crawley and Joseph Hoet describe 
the Declaration ofHelsinki as "the cornerstone of biomedical research 
for the last 30 years [and] the largely unquestioned anchor for ethical 
decision-making in clinical trials. "76 Moreover, many medical jour­
nals, such as the New England Journal of Medicine, require that re­
searchers publishing articles concerning clinical trials meet the ethical 
requirements of the Declaration of Helsinki.77 In May 2002, the 
United Nations Programme on HIV and AIDS (UNAIDS) included 
the Justice principle from the Declaration of Helsinki in its guidance 
document, Ethical Considerations in HIV Preventive Vaccine Research, 
which is now being used by researchers and foreign governments in 
structuring clinical HIV vaccine trials in developinG countries.?/; Al­
though many researchers acknowledge the significance of the ethical 
protections in the Declaration of Helsinki and the Belmont Report, 
some researchers continue to disregard the Justice requirement dis­
cussed in these documents and use Africans to bear the burden and 
72. [d. at 16. 
73. WORLD MED. ASS'N, supra note 13. 
74. Id. : see also The Belmont R"port. 44 Fed. Reg. 23,192, 23,197 (Apr. 18, 1979). 
75. The Delmont Report, 44 Fed. Reg. at 23,196. 
76. Francis Crawley & Joseph Hoet, Fthics and Law: 1he Declaration of Helsinki Under Dis­
cussion, 150 BULL. Mu). En-llcs 9, 10 (1999). 
77. Marcia Angell, Erhical Imperialism ? Erhics in international Collaborative Clinical Re­
search, 319 NEW ENG. J. MED. 1081, 1082-83 (1988). 
78. UNA IDS, Ethical Considerations in HIV Preventive Vaccine Research (2002), at http:// 
www.unaids.org (last visited Feb. 4, 2004). 
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risk of the research, while giving the benefit of the results of the re­
search only to citizens of developed countries.79 This was the case in 
the now defunct HIV drug trials conducted in Africa in the 1990s.80 
III. HIV DRUG TRIALS IN AFRICA 
A. Brief History of AZT Clinical Drug Trials in the United States 
and in Africa 
In February 1994, the AIDS Clinical Trials Group Study 076 (Study 
076) was concluded in the United States.81 Study 076 showed that 
orally administering the drug Azidothymidine (AZT) to HIV-positive 
pregnant women in the second trimester of pregnancy, intravenously 
during labor, and orally to newborns upon birth reduced perinatal 
transmission of HIV by two-thirds.82 This regimen of AZT cost $800 
per patient in U.S. dollars.S3 The expense of this regimen limited the 
accessibility of this treatment, so researchers began to search for a 
shorter, less expensive version of this AZT regimen, hut they were 
uncertain about what research design method to use to test this new 
regimen. In June 1994, the World Health Organization84 convened a 
group, which included no ethicists, in Geneva, and in an unpublished 
report, the group concluded that replicating Study 076 was neither ec­
onomically nor structurally feasible in developing countries.85 In­
stead, they concluded: "[P]lacebo-controlled trials offered the best 
option for a rapid and scientifically valid assessment of alternative an­
tiretroviral drug regimens to prevent [perinatal] transmission of HIV 
[in developing countries]."86 
Documents from the Centers for Disease Control and Prevention 
(CDC) after the Geneva meeting show that eighteen clinical trials 
studying interventions to prevent perinatal HIV transmission were in i­
tiated.87 These trials tested a variety of interventions to prevent per­
79. Varmus & Satcher, supra note 25, at 1004. Studdert & Brennan, supra note 19. at 546·48. 
80. A nnas & Grodin, supra note 23, at 560-6l. 
81. /d.; Bayer, supra note 21 , at 567. 
82. Perinatal transmission of HIV is when an HIV-positive pregnant woman gives the di sease 
to her newborn child. Annas & Grodin, supra note 23, at 560-61. 
83. Bayer, supra note 21, at 570; Varmus & Satcher, supra note 25, at 1004. 
84. The World Health Organization (WHO) is the health organization 01 th~ United Nations. 
See http://www.who.int/country/en (last visited Feb. 4, 2004). All countries that are members of 
the U nited Nations may become members of WHO by accepting its constitution. Id. The 
United States is a member of WHO. Id. 
85. Bayer, supra note 21, at 570; see also Lurie & Wolfe, supra note 24, at 854. 
86. Researchers used this unpublished document to justify their u:;e of placebus in subsequent 
AZT drug trials in developing countries instead of providing the long treatment of A7T th at was 
given to American research su bjects. Lurie & Wolfe, supra note 24, at 854. 
87. Jd. 
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The researchGrs conducting trials in Africa failed to provide AZT to 
all the subjects.9R Instead of giving African subjects the longer treat­
ment of AZT that U.S. subjects were given, researchers gave pregnant 
African women participating in the study placebos, even though it is 
widely accepted that placebos cannot be used if a known treatment is 
available.99 Because of the use of placebos, it was estimated that 1,000 
babies contracted HIV.IOO In addition to this reprehensible act, the 
benefits of these clinical trials were not fairly or equitably distributed 
between the U.S. and African populations used for the clinical trials. 
B. Who Benefited from the AZT Drug Trials Conducted in Africa? 
The societal benefit from the AZT drug trials was gaining access to 
a shorter-length treatment of AZT that prevented perinatal HIV 
transmission. In this case, access to this drug was determined by the 
cost of the treatment. The CDC estimated that the cost of the shorter­
length treatment of AZT was fifty dollars per patient, plus an addi­
tional ten dollars per patient charge for the initial HIV test to deter­
mine who was infected.l°1 The cost of sixty dollars per patient for the 
short treatment of AZT made the drug accessible to most Americans 
with or without health insurance.l°2 In the 1990s, the United States 
spent approximately $3,000 per patienPOJ However, the shorter­
length treatment of AZT tested in the clinical trials conducted in Af­
rica was not financially feasible to the citizens of Africa and other 
developing countries. In the 1990s, when the majority of these trials 
were conducted, the amount spent on healthcare per patient in U.S. 
dollars in each African country was well below SIxty dollars per pa­
tient, as evidenced by Table 1. 
98. ld. 
99. See BEAUCHAMP & CHI LDRESS, supra note 4, at 451 ; Lurie & Wolfe, supra note 24, at 854­
55; Ange ll , supra note 77, at 1082. The wi thholding of AZT was especially egregious because the 
manufacturer of AZT usually made the drug available free of charge for use in clinical trials. 
Lurie & Wolfe, supra note 24, at R55. 
100. Dyckman , supra note 92, at 93 . 
101. Annas & Grodin , supra note 23, at 563. 
102. ld. 
103. The amount spent per patient in the United States jumped to ~4,178 in 1998. See OFFICE 
OF THE ACTUARY, CTRS. FOR MEDICARE & MEDICAID SERVS., TABLE 1: NATIONAL HEALTH 
EXPENDITURES AND SELECTED ECONOMIC INDICATORS, LEVELS AND AVERAGE ANNUAL PER­
CENT CHANGE: SELECTED CALENDAR YEARS 1980-2012 (2003 ), available at http://cms.hhs.gov/ 
sta tistics/nhe/projections-2002/tl (last visited Feb. 4, 2004) . 
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TABLE 1 
Health Care Expenditures of African Countries Involved in 

Perinatal HIV Transmission Prevention Trials104 

Country (Year) 	 Amount spent per patient (U.S. dollars) 
Burkina Faso (1992) 22 
Cote d' Ivoire (1995) 22 
E thiopia (1990) 5 
Kenya (1992) 13 
Malawi (1990) 11 
Tanzania (1990) 5 
Uganda (1994) 10 
Zimbabwe (1991) 86 
The countries listed in Table 1 were sites of the clinical AZT drug 
tria ls. Based on the numbers in Table 1, seven out of eight of these 
countries would not have been able to afford the sixty dollars per pa­
tient necessary to purchase and provide the short-length A ZT treat­
ment to infected pregnant women, unless they significantly increased 
health care spending.105 As a result of the short-length AZT trials 
conducted in Africa and other developing countries, these drugs were 
marketed and available to U.S. residents but not Africans.l06 Based 
on the amount spent per patient per year, clearly these African coun­
tries did not have access to the short-length treatment of AZT after 
the drug trials. Thus, the society that benefited most from the results 
of these trials only included populations from developed countries 
such as the United States. Many researchers and ethicists questioned 
whether these studies were just, because the African population did 
not benefit from the results of the African trials while the U.S. popu­
lation did benefit. 
C. 	 Justice or Fair Access?: The Debate over A ZT Drug Trials 
Cunducted in Africa 
Leading ethicists, physicians, and researchers on both sides of the 
debate wrote articles addressing the ramifications of applying differ­
104. Table reprinted from Annas & Grodin, supra note 23, at 564. 
105. Many researche rs could argue that any African country could decide to spend more per 
patient each year to purchase the drug. This discussion is important because it addresses the 
need of countries to prioritize the use of their resources for the good of their citizens. However, 
the decisions of African countries to spend an amount uf money on uther things besides health 
spending is beyond the ~,cope of this Article and still does not preclude researchers' responsibil­
ity to use a population that will benefit from the results of the research. If a drug is estimated to 
cost more than wha t is nurmally spent per year per patient the question is: Without a change in 
spending, will the population benefit from the research? 
106. Lurie & Wolfe, supra note 24. at 854-55. 
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ent standards of Justice in AZT drug trials conducted in the United 
States and in Africa.107 One critic of the trials , Dr. Marcia Angell , 
wrote in an editorial, "Human subjects in any part of the world should 
be protected by an irreducible set of ethical standards ...."108 Other­
wise, acceptance of this "ethical relativism" could result in widespread 
exploitation of vulnerable populations in developing countries partici­
pating in clinical trials. lo9 Researchers who conducted the short­
length AZT trials in Africa argued that the lack of money dedicated 
to paying for healthcare for Africans negated their duty to provide 
Africans access to the results of the trial: a shorter-length AZT treat­
ment.110 Therefore, because of cost limitations, researchers argued 
they should not be required to ensure ~hat thc populations used for 
the study actually benefited from the results.1l1 However, these asser­
tions show a patent misunderstanding of the Justice principle and its 
application. 
The statement of Justice in the Belmont Report demands, not ad­
vises, that populations not be unduly burdened with research that is 
unlikely to benefit them without mention of cosL1J2 According to the 
Belmont Report, Justice is used to evaluate what population should be 
used for research before the clinical trial is commenced to protect vul­
nerable populations from exploitation.1l3 Before research is con­
ducted, federal funding agencies, researchers, and drug companies 
must evaluate whether the population being used as subjects for the 
clinical trial will benefit, not when it conveniently becomes apparent 
after the conclusion of the research that the subjects will not be able to 
afford the treatment. If the decision that Africans will benefit from 
the results of the research is not made prior to the selection of re­
search subjects and countries, then what is the purpose for the re­
search other than exploitation?114 
Furthermore, in an article supportive of the AZT drug trials, the 
CDC and NIH, the institutions funding some of the drug trials con­
ducted in Africa, responded to these ethical questions by stating that 
Justice does not simply require that popUlations participating in 
107. Full issues of the New England Journal of Medicine, the Ameiican Journal of Public 
Health , and the Hastings Center Report were devoted to this topic. See generally 337 N EW E NG . 
J. MED. 1 (1997); 88 AM. 1. PUB. HEALTH 1 (1998); 28 HASTINGS C ENTER REP. 1 (1998). 
108. Angell, supra note 77, at 1083. 
109. ld.; Angell , supra note 23, at 847-48. 
110. Bayer, supra note 21, at 570. 
111. Id. 
112. The Belmont Report, 44 Fed. Reg. 23,192, 23,197 (Apr. 18, J979). 
113. ld. at 23,196-97. 
114. Lurie & Wolfe!, supra note 24, at 854-55; Annas & Grodin, supra nute 23 at 560-61; An­
geli, supra note 23, at 847-48. 
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clinical trials benefit from the results but also that developing coun­
tries have "equitable access to clinical trials. "115 According to the for­
mer Surgeon General and the former director of the NIH, Justice 
requires that vulnerable populations be allowed to participate in 
clinical trials without being barred by the unavailability of the result­
ing treatment. 116 Hence, it is unjust if researchers do not conduct 
clinical trials in developing countries because it limits the ability of 
Africans to benefit from the trials.! 17 
This viewpoint alludes to the theory of fair opportunity espoused by 
Norman Daniels. That theory states that everyone should have a fair 
opportunity to resources, such as healthcare.118 Fair opportunity is a 
precept of Justice; however, fair opportunity without fair or equal dis­
tribution of benefits is unjust. Mere access to clinical trials without 
providing access to trials that benefit developing countries under­
mines the very principle of Justice stated in the Belmont Report and 
the Declaration of Helsinki. The Belmont Report states that Justice 
demands that researchers conducting clinical trials do not "unduly in­
volve persons from groups unlikely to be among the beneficiaries of 
subsequent applications of the research"; otherwise, the groups will be 
exploited because they are easily accessible.!19 So, even if fairness re­
quires equal access to clinical trials, these trials are not just unless a 
benefit is given to the population. 
This statement regarding fair access to participation in clinical trials 
is further misguided because it focuses on the benefits of individual 
citizens, rather than on the benefits to the population, which the Jus­
tice principle addresses. Justice is defined in terms of protection of 
the population not just protection of the individual participating in the 
research trial.120 In fact, the Belmont Report and the Declaration of 
Helsinki state that it is not enough for the participants of the clinical 
trials to be offered a benefit from the research; the population from 
which the subjects are a part must actually benefit.121 Thus, Justice 
requires researchers to select populations to use as subjects in clinical 
trials based on the populations' ability to benefit from the research. If 
115. Varmu~ & Saieher, supra note 25, at 1003. 
116. [d. 

117 [d. 

118 DANIELS, supra note 37, at 34-58. 

119. The Belmont Report, 44 Fed. Reg. 23,192, 23,194 (Apr. 18, 1979). 
120. In the Belmont Report, the protections of individuals participating in clinical trials are 
addressed by Respect for Persons and Beneficence. [d. at 23,192-96. These principles focus on 
ensuring that the subjects ' choices are voluntary (Respect for Persons) and that subjects are not 
sacrificed for the benefit of society (Beneficence). Id. at 23,192. For a full definition of each 
prinCiple, see supru noks 9 and 10. 
l21. The Belmont Report, 44 Fed. Reg. 23,192, 23,196 (Apr. 18, 1979). 
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the popUlation will nC't benefit from the results of the research then, 
according to the Belmont Report and Declaration of Helsinki, it IS 
neither justifiable nor ethical to use it for the benefit of others.122 
Many of the African HIV drug trials funded and conducted by the 
United States were abruptly halted because of pressures placed on 
researchers and funding agencies to conform to the ethical standards 
used in the United States. J23 Accordingly, these actions suggest that 
U.S. researchers from developed nations recognize the Justice princi­
ple's requirement in selecting research subjects from populations 
based on who will benefit from the results of the studies. To evaluate 
whether clinical researchers are currently abiding by the dictates of 
Justice , one can review the current HIV vaccine trials being conducted 
in Africa . 
IV. HIV VACCINE TRIALS IN AFRICA: ARE THE TRIALS U~]UST? 
A. The Structure of Clinical HIV Vaccine Trials 
The purpose of clinical HIV vaccine trials is to develop a vaccine 
that will either prevent the disease. as in the case of the smallpox vac­
cine, or slow the progression of the disease, as in the case of the flu 
vaccine.124 To develop an effective HIV vaccine through clinical tn­
als , researchers must complete three phasesY''; Phase I is conducted 
using a small number of subjects, usually less than fifty people, to ob­
tain information regarding the safety and effect of the candidate vac­
cine on human suhjects.126 Information regarding the immune 
system's response to the vaccine, the effect of the vaccine on different 
populations, and the effect of different doses on the population is 
gathered from several hundred subjects in Phase II trials.127 Phase III, 
the final phase of vaccine clinical trials before the vaccine is patented 
or discarded, is used by researchers to determine the efficacy of the 
vaccine for preventing the disease by following several thousand sub­
122. [d. at 23,197; see also WORLD M E D. ASS'N, supra note 13. 
123. Varmus & Satcher, supra note 25, at 1004. 
124. There an; many types of HIV vaccines being tested , but they can be separated int() tW() 
main categories: prophylactic and therapeutic. See Peter Lurie e t a!., Ethical, Behavioral, and 
Social Aspects of HIV Vaccine Trials in Developing Counlries, 26 JAMA 295, 295 (1994). Pro· 
phylactic vaccines were developed to prevent HIV infection , while therapeutic vaccines delay or 
prevent the progression of HIV to AIDS. Id. The difference in purpose of the vaccine being 
tested can also raise additional ethical issue concerning Justice, but this topic is outside the scope 
of this Article. 
125 . Id. at 297; Esparza, supra note 3, at 1133. 
126. Id. 
127. Id. 
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jects.128 Under each phase of the trials, subjects are given a number of 
vaccine doses and then tested for HIV several months later.129 
In 1987, the first Phase I clinical trial for the HIV vaccine was con­
ducted in Zaire.l3O Since 1987, sixty Phase I and II trials have been 
conducted, testing more than thirty candidate HIV vaccines.131 Most 
of the studies have been conducted in the United States and in Eu­
rope; and Phase III trials have only been conducted in the United 
States and Thailand, not in Africa,l32 This is important because only 
Phase III trials provide information concerning the effectiveness of 
the HIV vaccine to prevent HIV infection,133 Currently, researchers 
are conducting three Phase I HIV vaccine trials in the African coun­
tries of Botswana, South Africa, and Uganda,134 The U.S. govern­
ment funded the Botswana and South Africa HIV vaccine trials, while 
the IAVp35 funded the Uganda trials,136 Because these trials com­
menced in 2003, it is hard to determine whether the results of the 
study will benefit Africans. A review of these three vaccine trials 
shows some improvements from the AZT clinical trials but still raises 
questions regarding what "society" will benefit from the trials. The 
main question is whether a successful H IV vaccine will be accessible 
to Africans. 
B. Issues Concerning Current HIV Clinical Vaccine Trials137 
The benefit to African society for participating in the three HIV 
vaccine trials is actual access to a vaccine that will prevent new HIV 
128. Id. 
129. Lurie et aI., supra no~e 124, at 298. 
130. Little is known about the first trial other than the fact that Dr. Zagury. who conducted 
the trial, did so in Zaire because of the easy accessibility of research subjects, seemingly a viola­
tion of the ethical principle of Justice. See Christakis, supra not<.: 27. at 31. 
131. Esparza, supra note 3, at 1133. 
132. ld. 
133. [d. 
134. The trials in South Africa and Botswana began "ecruit ing palients in 2003 while the 
Ugandan trial has been underway since February 2003. See Int'l AIDS Vaccine hitiative, FOCLI ,~ 
on Developing Countries, at http://www.iavi.orglvaccinedev/developing.htm(la <. tvisited Apr. 22, 
2004) ; see also Nat' l Inst. of Health, Safety of an l-llV Vaccine (AVX IOI) in HIV Uninfected 
Volunteers in the United Slates and South Africa (2003), at http://www.C\inicaltriab.gov/ct/show/ 
NCT00063778?order=q (last visited Feb. 4, 2004) [hereinafter Nat'! Inst. of Health. AVXIOI]; 
Nat 'l Inst. of Health, Safety of and Immune System Response to an HIV Vaccine (EP HIV-IOOO) 
in HIV Uninfected Adults (2003). at http://www.clinicaltrials.gov/ct/showINCT000548b6?order=2 
(last visited Feb. 4, 2004) [hereinafter Nat'l Inst. of Health, EP HIV-I090]. 
135. IAVI is an international nonprofit organization that is headquartered ifl the United 
States. For more information, see supra subpart III(B). 
136. See sources cited supra note 134. 
137. There is some dispute when, and in what country, the first HIV vaccine trial was 
conducted based on the most prevalent types found in Africa. There are two sources that 
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infections or decrease the number of deaths from AIDS.l38 Develop­
ing an effective vaccine for Africans is complicated because individual 
Africans are infected with different types and strains of HIV between 
themselves and a different type and strain of HIV than with which 
Americans are infected.139 The discussion of the specific differences 
in types and strains of HIV is beyond the scope of this Article; how­
ever, it is because of this diversity in types and strains of infections 
that many researchers believe that a vaccine, which prevents one type 
of HIV infection, will not be efficacious in preventing infection by an­
other strain.140 Instead, researchers will probably need to develop a 
different HIV vaccine to prevent each of the major types and strains 
of HIV.141 This problem has been addressed in each of the vaccine 
trials conducted in Africa.142 In the Botswana trial. researchers are 
using a vaccine based on a combmation of the infection most preva­
lent in the United States and in Africa.143 In the trials in South Africa 
and Uganda, researchers are using an HIV vaccine based on the most 
prevalent type of infection in that region.144 Yet, it is still questiona­
ble whether Africans will benefit from any of these studies because of 
the limited monetary resources available to pay for a vaccine.l45 
suggest that the first trial started in Kenya in 2001. See In!'1. AIDS Vaccine Initiative, supra note 
134; AIDS.Org, First Vaccine for Africa Begins Trials (Jan. 26, 2001), at http://www.aids.orglatn/ 
a-359-02.html (last visited Nov. 5,2003). Susan Mayor, AIDS Vaccine Trial Begins in Uganda, 
326 BRITISH MLD. 1. 414 (2003). The literature is also unclear on whether the Kenya study has 
been concluded. See Int'l AIDS Vaccine Initiative, supra note 134. Thus, this trial will not be 
discussed in further detail in this Article . 
138. The difference in benefit depends on what type of HIV vaccine i~. being tested. If a 
prophylactic vaccine is effective, it would prevent HIV infection after exposure, while a thera­
peutic vaccine would only slow the progression of HIV to AIDS. See Lurie & Wolfe , supra note 
24, at 854-55. Further discussion of the consequence of developing different types of vaccines for 
use in the United States is beyond the scope of this Article; however, the author is in the process 
of drafting an article to discuss the burdens and benefits of the different types of vaccines in 
respect to the Justice principle. 
139. Esparza, supra note 3, at 1133. 
140. Id.; Lurie et aI., supm note 124, at 297. 
141 . ld. 
142. See Press Release , First HIV Vaccine Trial Commences in South Africa (Nov. 3, 2003), 
available at http://www.mrc.ac.za/pressreleases/2003/37pres2003.htm (last visited Feb. 4, 2004); 
see also Mugerwa et aI., supra note 30, at 228. 
143. See Jenny Badner, Botswana & Harvard: Teaming Up To Find an AIDS Vaccine, Voice of 
America, available a/ 2003 WL 59719040. 
144. ld. 
145. Even before HIV vaccine trials were launched in Africa, there was speculation from 
many U.S. physicians and ethicists regarding the lack of HIV vaccine trials based on the types of 
infection most prevalent to Africa. Dr. Peter Lurie, an American researcher and ethicist, '.tated 
that it was important that vaccine trials included strains from Africa because the majority of HIV 
infections were located in Africa. See Lurie et aI. , supra note 124, at 297. Additionally, Dr. 
Lurie suggested that trial sites of HIV vaccine clinical trials be located in different developing 
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The Botswana trial is conducted by the HIV Vaccine Trial Net­
work,146 the medical schools of Harvard University in Boston and St. 
Louis University in St. Louis, and funded by the NIH. The HIV trials 
in Botswana are using the same vaccine currently being tested in trials 
in Boston and St. Louis. Because these trials are being conducted in 
the United States and in Africa, positive results from the trials pro­
mote the possibility that a multinational vaccine, which would benefit 
a broader society, would be developed. However, the possible bene­
fits also create ethical dilemmas. There is no guarantee that the com­
pany manufacturing the vaccine will price it at a level affordable for 
the Botswana population. Instead, the company could simply decide 
to sell the vaccine to Botswana and the United States at a price afford­
able for the United States. Arguably, this would make the vaccine 
accessible to the population of Botswana. Notwithstanding this access, 
no one in Botswana would be able to afford to buy the vaccine, and 
therefore, the Botswana population would not realize the benefits of 
the research trial. 
To address this issue of access, the researchers from Harvard Uni­
versity are currently conducting studies in Botswana to create health 
infrastructures to treat HIV infection and a fellowship program to 
train scientists to conduct research in developing countries, such as 
Botswana. But, this neither addresses the issue of afford ability of the 
vaccine nor guarantees that the citizens of Botswana will realize the 
benefits of the trial: access to the vaccine if it proves effective. The 
failure of Africans to realize the benefits of clinical trials is not an 
uncommon occurrence. This is what happened in the AZT drug trials 
conducted in the 1990s in the United States and Africa. Although the 
results of those trials, a shorter-length treatment of AZT, were of­
fered to both the United States and Africa, only the United States 
could afford to provide the treatment to its citizens.147 Thus, those 
trials violated the Justice principle, as espoused in the Belmont Re­
port, because Africans bore the burden but failed to receive the bene­
fit from the trials. As in the case of those trials, if the Botswana trial 
nations such as in Africa, otherwise the vaccine will disproportionately benefit one population 
while shouldering the burdens with others. Id. 
146. In 1999, the HIV Vaccine Trial Network was formed by the Division of AIDS of the 
National Institute of Allergy and Infectious Diseases (NIAID), a component of the National 
Institutes of Ht:alth (NIH), when the federal government reorganized. See About the HIV Vac­
cine Trial Network (2003), at http://www.hvtn.orglabout (last visited Feb. 4, 2004). Since that 
time the HIV Vaccine Trial Network has blossomed into an international organization dedicated 
to conducting international HIV vaccine trials composed of twenty-seven research institutions 
worldwide and headquartered at the Fred Hutchinson Cancer Rest:arch Center. ld. 
147. Lurie & Wolfe, supra note 24, at 854-55. 
1148 DEPAUL LAW REVIEW [Vol. 53:1127 
fails to provide an actual benefit to the population of Botswana, the 
trial would violate the Belmont Report's Justice principle , because the 
"society" bearing part of the burden, the Botswana popUlation, would 
receive none of the benefits of the research. This is also a problem in 
the South African HIV vaccine trial. 
The South African trial is being conducted by the HIV Vaccine Trial 
Network and funded by the NIH in conjunction with the Medical Re­
search Council for South Africa (MRC). Testing has recently begun, 
but there is no mention in the literature whether the vaccine, if effec­
tive, will be accessible to the population of South Africa.148 The 
MRC's guidelines on ethics in medical research state that any result 
from research supported by MRC vests rights in MRC to patent the 
product of the research.H9 However, the guidelines also allow finan­
cial sponsors to have full rights to the results of the research, making 
the HIV Vaccine Trial Network or NIH or both , the owners of the 
vaccine patent.1so Without further information, it is impossible to de­
termine whether the trials will provide a benefit to the South African 
population that it is testing. The past has shown, however, that after 
studies are concluded there is no guarantee that African society will 
have actual access to the treatment tested. Thus, the failure of the 
HIV Vaccine Trial Network or the NIH to pledge access to the vaccine 
if it proves effective in either the Botswana or South African trial 
leaves the door open for violations of the Justice principle that oc­
curred in past AZT drug trials. 
The Uganda trial conducted by IAVI, an international scientific, 
nonprofit organization founded in 1996, seems to be the one HIV vac­
cine trial most likely to produce a benefit for the African popula­
tion ,lS1 Concerned with reports of vaccine researchers and 
manufacturers using clinical trials in poor countries to exploit weaker 
ethical protections for conducting biomedical research, the Ugandan 
government negotiated an agreement with IAVI that the vaccine, if 
effective, be accessible to the local population.152 This agreement 
148. See Press Release, First HIV Vaccine Trial , supra note 142. 
149. GUIDELINES ON ETHICS FOR MEDICAL RESEARCH, OWNERSHIP OF RESULTS: PATENT 
RIGHTS, COPYRIGHT, AND CONFIDENTIALITY (1993), available at http://www.mrc.ac.za/e thics/ 
ownership.htm (last visited Feb. 4, 2004). 
150. MED. RESEARCH COUNCIL, GUIDELINES ON ETHICS FOR MEDICAL RESEARCH, OWNER­
SHIP OF RESULTS OF RESEARCH (1993), available at http://www.mrc.ac.za/ethic./ownership. htm 
(last visited Feb. 4, 2004) (discussing ownership rights of financial sponsors). 
151. The main purpose of IAVI is to accelerate the development of safe, effective, and accessi­
ble HIV vaccines globally. Page, supra note 16, at 57. To achieve this end, IAVI provides money 
for private industry to develop and test HIV vaccines and then links the industry to foreign 
countries for testing. [d . 
152. Mugerwa et aI., supra note 30, at 228. 
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seemingly ensures that Ugandans wili benefit from the results of the 
vaccine trials, but what is "accessible '''! Uganda does not have the 
intellectual property rights to the vaccine, the infrastructure to admin­
ister the vaccine, or the right to manufacture the vaccine. l53 Thus, the 
same problem that arose in Uganda in 1997 during the AZT drug trial 
studies could reoccur. In 1997, Uganda only spent ten dollars per pa­
tient per year on health care; thus, they could ill afford to provide the 
shorter length AZT treatment at sixty dollars per patient to pregnant 
women to prevent perinatal HIY transmissionP4 If the vaccine is 
more than what Uganda currently spends per patient per year, then 
Ugandans may not actually have access to a vaccine, and the trials will 
be unjust. 155 
C. Solution to Promote Justice in All International Clinical Trials 
Both the South African and the Ugandan HIY vaccine trials pose a 
new quandary for ethicists: how to regulate clinical trials funded and 
conducted by different countries or private companies. Neither trial 
would exclusively fall under the realm of the Belmont Report because 
the U.S. government does not wholly fund the research. The Declara­
tion of Helsinki could be used to regulate the researchers conducting 
the trials, because each of the studies is conducted in part by foreign 
entities, thus triggering international law; however, the Declaration of 
Helsinki is only advisory. To rectify this problem, some scholars have 
suggested the use of prior agreements between foreign countries and 
researchers regarding the benefits of the research as the best way to 
address the ethical requirements of Justice; however, prior agreements 
pose the same problem as using the Declaration of Helsinki-there is 
no enforcement mechanism.l56 
As discussed above, IAYI and Uganda entered into a prior agree­
ment regarding the accessibility of an effective HIY vaccine. Al­
though the agreement between Uganda and IAYI purports to ensure 
that Ugandans have access to an effective vaccine, Uganda does not 
153. [d. 
154. Annas & Grodin, supra note 23, at 564. Currently, Uganda only spends $6 per year per 
patient , while the United States spends approximately $5,775 per patient. See VlUgerwa et aI., 
supra note 30, at 228; see also OFFICE OF THE ACTUARY, supra note 103. 
155. Uganda does have its own ethical requirements, but the requirements reiating to the 
Justice principle are advisory. The Uganda National Consensus Conference Guidelines for the 
Conduct of Health Research Involving Human Subjects in Uganda requires a researcher only 
make a reasonable effort to secure the product's availability to the local community in which the 
research occurred. See NATIOt;AL CONFERENCE, GU IDELINES FOR THE CONDUCT OF HEALTH 
RESEARCH INVOLVING HC\1AI' SUBJECTS IN UGANDA § V(D)(4) (1997), cited in Page, supra 
note 16, at 51 n.58. 
156. Page, supra note 16. 
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have any more enforceable mechanism to challenge the manufacturer 
than it did under the Declaration of Helsinki. IAVI has implemented 
a number of legally enforceable contractual measures including trans­
ferring the rights to produce the vaccine to another manufacturer if 
the manufacturer is unwilling to provide the HIV vaccine at a price 
that Uganda can afford, but this legally enforceable remedy is not 
available to U ganda. 157 IAVI retains all rights and powers to the pro­
duction of the vaccine. Therefore, lAVI, a private organization, can 
decide whether or not to enforce its contracts with private manufac­
turers for the benefit of Uganda. If IAVI decides not to enforce the 
provision, Ugandans will not receive any benefit from the results of 
the trials. 
Another possible solution to prevent the continued exploitation of 
Africans and the perversion of the Justice requirement is the creation 
of an international compulsory standard of ethical protections of 
human subjects participating in clinical trials. The standards would be 
drafted, implemented, and enforced by one international body. The 
United Nations Programme on HIV and AIDS has become the pre­
mier international organization in terms of HIV and AIDS research 
and would be the best place for this newly formed international regu­
latory body. For the organization to be effective, the standards must 
have penalties if they are violated, and the organization must have 
some ability to enforce their decisions. The organization's ability to 
enforce this standard will be subject to the structure of its governing 
document and the membership of the organization. If the document 
mirrors some of the current standards already compulsory in the 
United States under the Belmont Report and already agreed to by 
many medical professionals under the Declaration of Helsinki, then 
more countries will opt to comply because it will not challenge the 
status quo. Furthermore, if the membership of the organization in­
cludes the United States and key members of the European Union, 
researchers from those countries will comply with the dictates of the 
organiza tion. 
However, membership to the organization must be balanced to in­
clude many of the developing countries being exploited. To be fair in 
combating ethical violations in developing countries , the membership 
of the organization must be proportionate to the amount of research 
conducted in a country by researchers from other countries. With the 
creation of this compulsory international statement of ethics and en­
forcement, researchers and private funders will be held accountable 
157. ld. at 59. 
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for their ethical violations and deterred from committing the violation 
again, thus protecting vulnerable populations from exploitation. Pri­
vate funders and pharmaceutical companies may try to argue that 
their research is private and not subject to the mandates of an interna­
tional organization; however, researchers from member countries will 
be required to follow the dictates of the organization, and, thus, their 
funders must comply in order to conduct research in developing na­
tions. This is the best way to ensure that Africans are not exploited 
for the benefit of other populations, because it empowers the ex­
ploited society to protect its own citizens through enforceable means, 
rather than leaving them to rely on the mercy of a private entity. 
V. CONCLUSION 
The large number of persons infected with HIV in Africa combined 
with the inadequate monetary resources for purchasing medications to 
treat HIV-infected persons makes Africa ideal for conducting HIV 
vaccine trials.158 However, in light of the recent history of the AZT 
drug trials in which Africans were exploited,159 Africans were con­
cerned about reports in the foreign media that manufacturers might 
choose to test vaccines in poor countries to reduce product liability in 
case of injury or to exploit weaker legal, ethical, or regulatory mecha­
nisms for conducting biomedical research.160 In fact, many Africans 
"asked whether the [HIV vaccine] trial was an example of 'hit and run 
research' by scientists from rich countries, in which a poor country 
was chosen as the setting because the study would be cheaper and 
fewer questions would be asked about safety and ethics."lul As 
clinical HIV vaccine trials commence, Africans wonder if they will re­
ceive any benefit as a society from the research or will simply be 
exploitcd.162 
In the past, there has been much discussion regarding the require­
ment of providing a benefit to an African society after conducting an 
HIV clinical trial in Africa. 163 Some have lauded the research com­
lSi':. Id. 
159. An example of exploitation of Africans used in clinical trials was the 1990 AZT drug 
trial s. For more information, see supra subpart II(B). 
160. ld. 
161. See Mugerwa et at , supra note 30, at 228. 
162. rd. 
163. See generally id.; David Orentlicher, Univ ersality and Its Limits: When Research Ethics 
Can Reflect Local Circumstances, 30 J.L. MED . & ETJ-Hes 403 (2002); Joanne Roman, Note, us. 
Medical Research in the Developing World: Ignoring Nuremberg, 11 CORNELL J.L & Pt ~fl. POt 'y 
441 (2002). 
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munity for giving Africans equitable access to clinical trials,164 but 
mere access to trials without any guarantee that the results of the tri­
als will provide a benefit to Africans leaves them with the burden but 
no benefit. Both the Belmont Report and the Declaration of Helsinki 
require that the population studied receive a benefit to ensure that 
populations are not exploited or used in trials for the benefit of 
others.165 In the current HIV vaccine trials, the very structure of 
clinical trials would negate any significant benefits individual Africans 
would receive from participating in clinical trials. Because these 
Phase I clinical trials are merely evaluating the safety of the vaccine 
versus the dangers and side effects of the vaccine, the net benefit from 
the trials is to the society that gains access to an effective vaccine after 
Phase III trials, not the participants in the clinical trials. 
Therefore, rather than focusing on mere access to trials, there is a 
need for researchers to shift their thinking and perception of the bene­
fits of clinical trials in Africa. The key to this shift is to focus on the 
fact that the benefit researchers are trying to obtain is for society. So­
ciety includes all countries but specifically the country researchers 
used for the research. Thus, as researchers choose research subjects 
for HIV vaccine trials in Africa , they should make the choice based on 
the view that research is conducted to save human lives, which in­
cludes the lives of the people in the country where clinical trials are 
conducted. Simply viewing these subjects as dispensable figures ne­
glects not only the spirit of the research subject protocol rules but also 
violates the letter of the rule. The Belmont Report and the Declara­
tion of Helsinki require that the population benefit from the research, 
not simply that the researchers offer the population a benefit; other­
wise, the research is not justified.166 Unfortunately, the Belmont Re­
port and the Declaration of Helsinki do not protect all research 
subjects. The Belmont Report is only compulsory for research funded 
by the United States, while the Declaration of Helsinki is only a guide 
to researchers. 
To prevent this gap in protection, some scholars have suggested pro­
moting prior agreements between the researchers, funders, and the 
foreign country.167 However, these agreements are not always en­
forceable and can lead to different outcomes for different countries 
based on the power base of the country negotiating the deal. A better 
164. Varmus & Satcher, supra note 25 , at 1004. 
165. The Belmont Report , 44 Fed. Reg. 23,192, 23,196-97 (Apr. 18, 1979); see also WORLD 
M ED. ASS'N, supra note 13. 
166. The Belmont Report, 44 Fed. Reg. at 23,194. 
167. Page, supra note 16. 
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way to prevent the continued exploitation of Africans is to create an 
international compulsory standard of ethical protections of human 
subjects participating in clinical trials enforced by an international 
body whose membership includes representatives from developing 
countries. With the creation of this compulsory international state­
ment of ethics and enforcement organization, researchers will be held 
accountable for their ethical violations in developing countries, which 
would deter them from committing the violations again and would 
protect vulnerable populations from exploitation. 
